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Abstract
Tumour immunotherapy has become a treatment modality for cancer, harnessing the immune
system to recognize and eradicate tumour cells specifically. It is based on the expression of
tumour associated antigens (TAA) by the tumour cells and aims at the induction of TAA-specific
effector T cell responses, whilst overruling various mechanisms that can hamper the anti-tumour
immune response, e.g. regulatory T cells (Treg). (Re-) activation of effector T cells requires the
completion of a carefully orchestrated series of specific steps. Particularly important is the
provision of TAA presentation and strong stimulatory signals, delivered by co-stimulatory surface
molecules and cytokines. These can only be delivered by professional antigen-presenting cells, in
particular dendritic cells (DC). Therefore, DC need to be loaded with TAA and appropriately
activated. It is not surprising that an extensive part of DC research has focused on the delivery of
both TAA and activation signals to DC, developing a one step approach to obtain potent
stimulatory DC. The simultaneous delivery of TAA and activation signals is therefore the topic of
this review, emphasizing the role of DC in mediating T cell activation and how we can manipulate
DC for the pill-pose of enhancing tumour immunotherapy. As we gain a better understanding of
the molecular and cellular mechanisms that mediate induction of TAA-specific T cells, rational
approaches for the activation of T cell responses can be developed for the treatment of cancer.
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GENERAL INTRODUCTION
The concept of a central role for the immune system in the treatment of diseases is
longstanding. Already a century ago George Bernard Shaw postulated that the stimulation of
phagocytes is at bottom the only genuinely scientific treatment for all diseases [1]. At the
same time, Paul Ehrlich formulated his immune surveillance hypothesis, stating that the
immune system can distinguish self from non-self and that the latter can be eliminated
without damaging the former [2]. He put forward the fundamental immunological idea of
unique receptors on immune cells. It took another 70 years to identify – what we now know
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as - the T cell receptor (TCR) (reviewed by [3]). Originally these concepts were devised for
explaining immune responses against foreign invaders. However, Burnet and Thomas,
translated these in view of anti-tumour immune responses in their so-called tumour
surveillance hypothesis, proposing a model in which tumour cells are recognized as foreign
by the immune system and subsequently specifically eliminated without damaging their
healthy counterparts, much in the same way as for virus infected cells, thus avoiding auto-
immunity [4].
The identification of antigens that are specifically expressed by the tumour, but not by
normal tissues offered a rationale for this hypothesis. These tumour-associated antigens
(TAA) can be divided in several groups according to their expression pattern [5]. As
melanoma constitutes the most immunogenic cancer, most of the TAA known to date were
identified from melanoma tumours. It has been demonstrated that each of these antigens can
give rise to a number of epitopes that will be presented in major histocompatibility (MHC)
class I or class II molecules and that these MHC/peptide complexes can be recognized by
the TCR of CD8+ cytotoxic T lymphocytes (CTL) and CD4+ T cells, respectively [6]. The
former are able to kill tumour cells by secreting cytolytic granules or activating death
receptor-associated apoptosis pathways, while CD4+ Th 1 cells secrete cytokines that assist
in the activation and maintenance of CTL, as well as in inhibition of tumour cell
proliferation [7]. Extensive research into these TAA and immune responses directed against
them has instigated attempts for the manipulation of the anti-tumour immune response by
actively trying to stimulate immunity - CTL and Th 1 cells - against these TAA and
consequently against the tumour itself. These therapeutic vaccination approaches have been
developed as an alternative or additional treatment regimen to classic therapies, such as
radiotherapy, chemotherapy and surgical removal of tumours.
It has to be mentioned that although cancer cells can potentially be distinguished from
normal cells through this arsenal of TAA, most of these TAA are still considered as auto-
antigens by the immune system. As a consequence, several tolerogenic mechanisms as well
as different modes of active inhibition will impede the induction of a productive anti-tumour
immune response. A manifestation of this phenomenon is the presence of high numbers of
CTL in the tumour and the periphery without measurable tumour regression [8]. Taken
together, for any therapeutic vaccination strategy to be successful, it is crucial not only to
induce a specific immune response against the tumour, but also to overcome intrinsic
tolerogenic and suppressive mechanisms.
DC-BASED THERAPY OF CANCER
Immunotherapy seeks to mobilize a patient’s immune system for therapeutic benefit. It can
be passive, i.e. transfer of immune effector cells (T cells) or proteins (antibodies), or active
through vaccination. In cancer, passive immunotherapy can lead to some objective clinical
responses, thus demonstrating that the immune system can reject tumours [9]. However,
passive immunotherapy is not expected to yield long-lived memory T cells that might
control tumour outgrowth.
Active immunotherapy using TAA and adjuvant has the potential to induce both tumour-
specific effector and memory T cells. In this regard DC, known as the professional antigen-
presenting cells of our immune system, are considered as nature’s adjuvant and are therefore
well studied as a cellular anti-cancer vaccine [10].
DC Subsets
DC were first visualized as Langerhans cells in the skin in 1868 by Paul Langerhans, then
Ralph Steinman and Cohn identified DC from mouse spleen in 1973 [11]. They constitute a
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distinct lineage of white blood cell development, which was originally thought to share a
progenitor with other phagocytes, such as macrophages and granulocytes. Although
granulocyte-macrophage colony stimulating factor (GM-CSF) was recognized as a key
stimulating cytokine for these populations, DC were regarded as a separate cell lineage,
because of their unique properties [12]. The intricate development and life cycle of DC is
reviewed in detail in numerous reviews [13-15]. In summary, DC can originate from both
lymphoid and myeloid progenitors, giving rise to several distinct subsets, which are defined
by the expression of surface markers and by their function [16]. Although the definition of
DC subsets in mouse is much more complicated than in human, they can be broadly divided
into myeloid DC and plasmacytoid DC. These DC subsets differ in their life span, cytokine
production, receptors for antigen uptake, receptors for microbial ligands, which are
essentially pathogen recognition receptors, such as toll like receptors (TLR), as well as
receptors for cytokines and chemokines and linked herewith their function. Plasmacytoid
DC, characterized by the expression of BDCA-2 and a relative long life span are able to
make high amounts of interferon-α (IFN-α) in response to viral infection [17, 18]. These
DC can – although very weakly - capture soluble and particulate antigens [19], respond to
IL-3 [20] and express TLR9, which engages bacterial DNA and demethylated CpG DNA
[21]. In contrast to plasmacytoid DC, myeloid DC respond to GM-CSF rather than IL-3 [22]
and are characterized by the high expression of CD11c and low expression of CD123 [23].
They express a number of endocytic receptors that are not found on plasmacytoid DC and
that enable them to efficiently sample the environment [15]. They are further characterized
by their ability to make IL-12 in response to several stimuli, amongst which ligands of
TLR2 (lipopeptides), TLR3 (dsRNA) and TLR4 (bacterial cell wall components) [24].
It has to be mentioned that although production of IFN-α is the major function of
plasmacytoid DC and production of IL-12 is the major function of myeloid DC, both can be
stimulated to produce IL-12 or IFN-α, respectively [25-27]. This cytokine pattern induced
upon interaction of pathogen associated patterns with pathogen recognition receptors is part
of an important final stage of DC differentiation, i.e. maturation, which comprises more than
up-regulation of cytokines and which is pivotal for determining the subsequent immune
response. The maturation of DC and the induction of immunity versus tolerance are
discussed in more detail in the following section.
Regulation of T Cell Immunity by DC
DC have a remarkable functional plasticity, inducing either tolerance or immunity. The
hypothesis is that distinct DC developmental and activation stages play a role in the
induction of tolerance versus immunity. This is correlated with the two-signal model of T
cell stimulation, in which it is proposed that a productive T cell immune response requires
specific recognition of MHC/peptide complexes by the TCR (signal 1) along with signalling
through co-stimulatory molecules (signal 2). Indeed both immature myeloid and
plasmacytoid DC, have been described to induce T cell tolerance [28-30], whereas both
mature DC types have shown to induce immunity [31-33].
Immature DC are specialized in capturing antigens. They efficiently take up pathogens,
apoptotic cells and antigens from the environment by phagocytosis, macropinocytosis, or
endocytosis, process these, but are considered to be unable to present these antigens
efficiently to T cells [34]. Therefore, immature DC are believed to induce T cell anergy and/
or Treg [35, 36]. Indeed, in steady-state conditions, DC remain immature and tissue-
resident, expressing small amounts of MHC molecules as well as co-stimulatory molecules,
hence inducing T cell anergy instead of T cell activation upon DC-T cell interaction [37].
Furthermore, injection of immature DC in humans can be tolerogenic [28, 38, 39]. On the
other hand, mature DC are considered to be immunogenic. Maturation of DC can be induced
by a variety of signals, such as microorganisms [40, 41], cytokines [42], interaction with
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CD4+ Th cells [43-45] and chemicals like haptens [46-48]. DC maturation is associated with
several coordinated events, including: (a) loss of endocytic and/or phagocytic receptors; (b)
changes in morphology; (c) up-regulation of MHC molecules, co-stimulatory molecules
such as CD40, CD80, CD83 and CD86, adhesion molecules and chemokine receptors, such
as CCR7 [10]. The latter is one of the first changes and enables the DC to migrate from the
peripheral tissue to the T cell areas of the draining lymphoid organs [49], where DC present
peptides, derived from antigens acquired in the periphery, in the context of MHC to passing
T cells. The phenotypic changes – high expression of antigen presenting, co-stimulatory and
adhesion molecules - make mature DC potent inducers of T cell immunity.
However, the view that immature DC induce tolerance and mature DC induce immunity is
simplified. It has been demonstrated that mature DC can contribute to T cell tolerance
through the induction of Treg [50]. It was suggested that it is the maturation trigger that
dictates the DC’s T cell polarizing or tolerating immune functions. Some triggers have been
demonstrated to promote production of cytokines, such as IL-12 and IFN-α, hence inducing
Th 1 responses. These include molecules derived from bacterial or viral products, such as
LPS, CpG motifs and dsRNA, pro-inflammatory cytokines, such as tumour necrosis factor-
α (TNF-α) and IFN-α, as well as T cell signals, mainly the interaction of CD40Ligand
expressed on CD4+ Th cells with CD40 expressed on DC [51]. By contrast, anti-
inflammatory molecules, such as IL-10 and prostaglandin E2 (PGE2) hamper full DC
maturation and cytokine production, thus resulting in the stimulation of Treg responses [28].
In summary, instruction of adaptive immunity occurs largely through triggering the
maturation of DC. When appropriately activated immature DC transform from highly
phagocytic, tissue-resident cells into highly immunogenic, lymph node-homing cells that are
competent to induce T cell responses to non-self antigens acquired in the periphery.
DC Activation in View Of Tumour Immunology: A Role for TLR
As mentioned in the general introduction, immune tolerance represents a major barrier in the
induction of effective cellular anti-tumour immune responses. This can be explained by the
fact that tumour cells arise endogenously and that most TAA are therefore recognized as
self. As a consequence, many T cells of the tumour-specific T cell repertoire have been
eliminated centrally or peripherally [52]. Additionally, tumour cells have acquired several
mechanisms to suppress T cells that have escaped this selection. These include antigen
presentation in the absence of co-stimulation, expression of inhibitory/death inducing signals
(e.g. PD-L1, FasL), expression of immunomodulatory enzymes (e.g. indoleamine-2,3-
deoxygenase) and secretion of immune suppressive cytokines and chemokines (e.g. IL-10,
transforming growth factor-β (TGF-β) [53].
Moreover, these secreted inhibitory factors not only suppress effector T cells, but also
promote the existence of immune cells with suppressive functions, such as Treg, regulatory
DC (DCreg) and myeloid-derived suppressor cells [54, 55]. In Fig. (1), the different
mechanisms of anti-tumour immunity and tumour-induced suppression mentioned
throughout the introduction are summarized (Fig. 1).
One of the paradigms of immunology is that a productive T cell immune response requires
specific recognition of an MHC/peptide complex by the TCR (signal 1) along with adequate
signalling through co-stimulatory molecules (signal 2). Recently, data indicate that to
establish strong anti-tumour responses, an inflammatory environment (signal 3) is required
alongside functional recognition of T cells by antigen-presenting cells. This can be achieved
by strong activation of the innate arm of the immune system, in particular through TLR. The
critical roles of TLR in activation of adaptive immune responses have been well documented
and extensively reviewed by [24, 56-58]. In summary, TLR have been shown to control
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adaptive immune responses at multiple levels, including the control of antigen uptake,
through the remodelling of the actin cytoskeleton, resulting in uptake of antigens via
macropinocytosis [59].
Furthermore, it was demonstrated that the efficiency of presenting antigens from
phagocytosed cargo is dependent on the presence of TLR ligands within the cargo. Blander
et al. demonstrated that the generation of peptide/MHC class II complexes is controlled by
TLR in a strictly phagosome-autonomous manner. The enhanced rate of phagolysosomal
maturation in the presence of signals from TLR2 and TLR4 has been clearly demonstrated
[60-62]. Thus, antigen sampling by DC is controlled by TLR and the engagement of TLR
signalling helps DC to distinguish between cargo containing self or non-self antigens, a
property that can be exploited to induce anti-tumour immune responses. These TLR further
control the maturation of DC, including their capacity to migrate, the up-regulation of the
co-stimulatory molecules CD40, CD80, CD86 and CD70 and production of primarily Th 1
cytokines like IL-1, IL-6, TNF-α and IL-12. The very fact that protective Th 1 cytokine
response can be achieved by using TLR signalling is another interesting property in terms of
anti-tumour immune responses [24, 56, 63]. Yang et al. showed that in order to break
tolerance of tumour-specific CTL, persistent TLR ligation should be provided alongside
antigen-loaded mature DC [64]. Similarly, Lang et al. showed that even in a transgenic
mouse model where the antigen is highly expressed in the target organ (in this case the
pancreas) adoptively transferred CTL were not able to actually lyse the target cells. Only
concomitant TLR ligand administration induced frank diabetes [65]. Besides a lack of
sufficient stimulation to break tolerance, several inhibitory mechanisms, such as the
presence of Treg need to be overcome. In mouse studies, it has been shown that depletion of
these Treg greatly enhances the anti-tumour response [66, 67]. Again, signalling through
certain combinations of TLR on DC not only provided a synergy with respect to the
production of cytokines such as IL-12 [68, 69], but also offers protection from Treg
inhibition [70]. From these data it is clear that the engagement of TLR signalling pathways
is a promising mechanism for boosting DC-based vaccine responses.
MECHANISMS OF TLR-SIGNALLING
Understanding the mechanism of TLR signalling and its correlated feedback mechanisms is
pivotal to the exploitation of these pathways for the pill-pose of enhancing DC-based
vaccines. Binding of TLR to their ligands, usually bacterial or viral-derived proteins and
nucleic acids trigger a complex network of signalling molecules and adaptor proteins that
will ultimately modulate DC responses in innate and adaptive immunity [24, 71, 72]. All
these signalling networks cooperate, integrate and finally converge into a few pathways,
such as that of mitogen-activated protein kinase (MAPK) and nuclear factor-κB (NF-κB)
[72-76]. In addition, these pathways interact with each other [77, 78]. It is this crosstalk
together with the strength, timing and context of stimulation that determines the type and
duration of immune responses [79-81]. The MAPK and NF-κB pathway are schematically
represented in Fig. 2 and will be discussed in more detail in the following sections.
Activation of MAPK Pathways in DC
MAPK are a diverse group of intracellular serine/threonine kinases firstly discovered in
yeast. They are phylogenetically conserved and regulate a wide range of cellular processes
ranging from cell growth, differentiation and survival to cellular stress and immune
responses [82]. Three groups of MAPK have been identified: the extracellular signal-
regulated protein kinases (ERK) [83, 84], the c-Jun N-terminal kinases (JNK) [85, 86] and
the p38 stress-activated protein kinases (p38) [87, 88]. They are structurally related and their
catalytic core is blocked by a conserved activation loop [89]. Phosphorylation of the
activation loop unblocks the catalytic site leading to phosphorylation of specific targets.
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Generally, MAPK activation starts at cellular membranes (plasma membrane or in
intracellular organelles) after the engagement of receptors to their ligands. MAPK pathways
consist on a three-modular cascade involving activating phosphorylations of downstream
kinases by upstream kinases. In this way, MAPK kinase kinases (MAPKKK) are firstly
activated by phosphorylation after their recruitment to the cytoplasmic domain of receptors
through multi-protein complexes. These phosphorylated MAPKKK subsequently
phosphorylate MAPK kinases (MAPKK), which in turn will phosphorylate MAPK.
In DC, MAPK are always activated after signal transduction from TLR. TLR are integral
membrane proteins with an extracellular domain that binds to molecular patterns, a single
transmembrane domain and a cytoplasmic domain. The TLR cytoplasmic tail contains the
Toll/IL-1 receptor (TIR) domain, essential for signal transduction [90]. Simplifying, mainly
(but not exclusively) two TIR-domain adaptor molecules, MyD88 (myeloid differentiation
factor 88) and TRIF (Toll/IL-1 receptor domain-containing adaptor-inducing IFN-β) are
recruited to the TLR TIR domain. Then, MAPKKK are activated through further
recruitment of various protein kinases and scaffold proteins, such as ubiquitin ligases TNFR-
associated factor 6 (TRAF6) and TRAF3 [91]. MAPK activation has been shown to depend
on MyD88-TRAF6-mediated recruitment of a complex containing MAPKKK TAK1
(transforming growth factor-beta-activated kinase-1) [92], but also in an alternative pathway
involving TRIF-TRAF3 [91]. However, there might be other pathways leading to MAPK
activation depending on the cell type or the type of stimulus. As an example, Ubc13 E2
ubiquitin-conjugated protein has been shown to regulate MAPK signalling through IKKγ
binding in B cells, independently of TRAF6-TAK1 [93].
The MAPK ERK Pathway
The extracellular signal-related kinase (ERK) comprises at least 8 isoforms from which
ERK1 and ERK2 are the most extensively studied. The classical ERK activation pathway
starts with the binding of growth factors to cell membrane receptors such as epidermal
growth factor receptor (EGFR) [94]. This results in Ras activation and association to the
MAPKKK Raf-1. Raf-1 subsequently phosphorylates MAPKK, MEK1 and MEK2
(MEK1/2), which in turn phosphorylate ERK1/2 threonine and tyrosine residues at its
activation loop. In fact, there is evidence that Raf-1 plays an important role in LPS-
dependent ERK activation during DC maturation [95]. However, this study was performed
in an immortalised murine DC2.4 cell line and it does not rule out the possibility of Raf-1
phosphorylation by MEK1 through a positive feedback mechanism [96]. In the context of
TLR-dependent ERK activation, TAK1 plays a prominent role [97]. However, ERK
phosphorylation was not completely abrogated in cells lacking TAK1 [92], suggesting
additional TLR-associated pathways leading to ERK phosphorylation. Classical ERK targets
range from kinases such as 40S ribosomal protein S6 kinase (RSK) to transcription factors
such as c-myc, cFos, ATF-2, Elk-1, Ets-1 and c-Jun just to name a few [98].
In DC, ERK is involved in cell survival [73], in regulation of inflammation and immune
suppression [99, 100]. In fact, ERK negatively regulates DC maturation through secretion of
immunosuppressive cytokines such as IL-10 and TGF-β [76, 77, 99-105]. As already
mentioned above, ERK is virtually activated by signalling through all TLR through TRAF6-
TAK1 and TRAF3, although it is preferentially activated by specific TLR such as TLR2
which promotes immune suppression and tolerance [75, 103, 105] or by other TLR
depending on the cell type and stimulation context [71, 106, 107].
Actually, inhibition of ERK phosphorylation with specific MEK inhibitors PD98059 and
U0126 enhances DC maturation, increases pro-inflammatory cytokine secretion and
counteracts tumour-induced immune suppression [101, 108-110]. Consequently, it is
tempting to speculate that some kinase inhibitors used in cancer chemotherapy [111] could
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be effective immune stimulators by ERK inhibition in antigen-presenting cells. In fact, the
tyrosine kinase inhibitor sunitinib, widely used in the treatment of metastatic renal cancer
among others, enhances anti-tumour immune responses by decreasing numbers of myeloid-
derived suppressor cells and Treg [112]. However, in this particular case, immune activation
was linked to inhibition of STAT3 phosphorylation, although some ERK inhibition was
observed [113].
The MAPK p38 Pathway
MAPK p38 comprises at least four splice isoforms from which p38α and p38β are
ubiquitously expressed. In the context of TLR activation, p38 phosphorylation is completely
dependent on TAK1 activity as shown in embryonic fibroblasts and B cells [92]. In fact, it
has been shown that TAK1 phosphorylates MKK3 and MKK6, the two main p38 MAPKK
[114, 115]. In turn, MKK3 and MKK6 phosphorylate p38 within its activation loop.
Classical p38 targets range from kinases such as MK2 and transcription factors such as ATF,
p53, c/EBPβ and NFAT just to mention a few [116].
MAPK p38 plays an important part in DC maturation and secretion of pro-inflammatory
cytokines. Therefore, it is not surprising that p38 inhibition is one of the most frequent
strategies for the treatment of auto-immune and inflammatory diseases [111]. In fact, LPS
and TNF-α-dependent up-regulation of DC co-stimulatory molecules and maturation
markers such as CD40, CD80, CD86, CD83 and MHC class II is inhibited by SB203580, a
specific p38 inhibitor [117]. Combined evidence from p38 specific inhibitors and KO mice
has shown that the p38 pathway is involved in secretion of IL-1β, TNF-α, IL-6 and IL-12
[117-119]. Accordingly, LPS-induced p38 activity could up-regulate transcription of
cytokine genes by ATF2 and CREB phosphorylation [82, 120]. However, there is evidence
that p38 activity on its own does not up-regulate pro-inflammatory cytokine genes [100,
121]. In fact, p38 induces changes in chromatin structure that allow NF-κB to bind to
cytokine promoters leading to their transcriptional transactivation [121].
Remarkably, MAPK p38 and ERK play antagonistic effects in many cell types, including
antigen-presenting cells such as macrophages and DC [101]. There is growing evidence that
ERK and p38 regulation is interconnected by several mechanisms. In macrophages, TGF-β-
activated ERK up-regulates MAPK phosphatase 1 (MKP1) that eventually dephosphorylates
p38 [122]. In some cases, p38 stimulates phosphatase PP2A activity, leading to MEK1/2
dephosphorylation [98, 123]. In zymosan-stimulated splenic DC, ERK leads to p38
dephosphorylation through up-regulation of suppressor of cytokine signalling 3 (SOCS3)
[105]. Moreover, direct interactions between ERK and p38 have been reported, adding a
potential regulatory level in both MAPK pathways [124].
The MAPK JNK Pathway
c-Jun N-terminal kinase (JNK) proteins are encoded by 3 genes with 10 or more alternative
splice forms [125]. From these, the JNK1 and JNK2 isoforms are the most extensively
studied. JNK is activated by UV irradiation, environmental and chemical stress, pro-
inflammatory cytokines and TLR signalling [91, 97, 114, 125]. JNK activation relies on its
dual phosphorylation of threonine and tyrosine residues by MAPKK, MKK4 and MKK7.
The classical JNK targets are c-Jun, from which it receives its name, ATF2, p53, Elk-1 and
c-Myc amongst others [98, 120, 125, 126].
ATF2 and c-Jun are components of AP-1, a transcription factor that transactivates many pro-
inflammatory genes. Consequently, JNK is involved in inflammatory responses and
inhibitors are being evaluated in clinical trials for the treatment of autoimmune diseases such
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as rheumatoid arthritis as well as asthma, inflammatory diseases and some types of
leukaemia [111].
In the context of TLR signalling, TAK1 is involved in JNK activation through MKK3 and
MKK7 phosphorylation [92, 97, 114, 127]. In general, JNK activity enhances DC
maturation and pro-inflammatory cytokine secretion, although at lower levels compared to
p38 [100, 128]. Treatment of DC with the specific JNK inhibitor SP600125 decreased LPS-
induced c-Jun phosphorylation, inhibited TNF-α and IL-12 secretion and slightly inhibited
up-regulation of co-stimulatory molecules CD80, CD86, CD83 and ICAM-I [128].
Therefore, JNK has been considered as a cooperative pathway together with NF-κB and
p38, rather than playing a central role in DC maturation.
The NF-κB Pathway in DC
NF-κB was first identified in 1986 as a transcription factor that binds to a 10 base pair DNA
element, consensus sequence 5′-GGGAATTTCC-3′ and its many variations, in the κ
immunoglobulin light-chain enhancer in B cells, hence its name [129].
The molecules that comprise the NF-κB family have been shown to be central to immunity
and inflammation [130]. Their importance in DC biology has been demonstrated by the
many DC-related defects in NF-κB KO mice [131-136].
The NF-κB family members exist as homo- or heterodimeric complexes formed by
combinations of five distinct DNA binding subunits, p65/RelA, RelB, c-Rel, p50 and p52.
Of these, RelA, RelB and c-Rel are synthesized in their mature forms and contain a
transactivation domain that interacts with the transcriptional apparatus. On the other hand,
p50 and p52 are synthesized in precursor forms, which contain C-terminal ankyrin repeats
that are proteolysed by the proteasome resulting in the production of mature proteins. Both
p50 and p52 contain a DNA binding domain, but lack a transactivation domain. It is
noteworthy that in particular RelB has been implicated in the differentiation and maturation
of DC. RelB-deficient mice lack mature myeloid DC [132, 137]. Furthermore, DC in which
RelB expression is inhibited retain an immature phenotype and are associated with induction
of immune tolerance in vivo [138].
All the NF-κB proteins are characterized by the presence of a highly conserved 300 amino
acid Rel homology domain that is located at the N-terminus of the protein. It is this domain
that is responsible for the dimerization and subsequent DNA binding. Furthermore, this Rel
homology domain interacts with specific inhibitory factors known as inhibitors of κB (IκB)
proteins. A number of different IκB proteins exist. These are IκBα, IκBβ, IκBγ, IκB and
Bcl-3. It is generally believed that the different isoforms are associated with particular Rel
protein dimers, bound via their Rel homology domain. For example IκBα and IκBβ
associate with RelA/p50 and p50/c-Rel, whereas IκB only binds to RelA and c-Rel hetero-
and homodimers. The binding of IκB to these dimers keeps these NF-κB dimers in an
inactive state, mainly in the cytosol. The NF-κB/IκB complex can shuttle between the
cytoplasm and the nucleus in unstimulated cells, but nuclear export of the complex is
inefficient and therefore, the NF-κB/IκB complex is mainly cytoplasmic in resting cells.
NF-κB can be activated by many divergent stimuli, including pro-inflammatory cytokines
(such as TNF-α, IL-1), T cell delivered signalling (CD40L), bacteria, viruses and cellular
stress (such as UV, ionizing radiation and chemotherapeutic agents), signals that mediate
DC maturation [139]. Different NF-κB activation pathways have been described [140, 141].
Essentially, these pathways share adaptor molecules with the above-described MAPK
pathways and can basically be divided into a classical (canonical) and non-classical pathway
[140, 142, 143]. Both pathways start a chain reaction of events resulting in the activation of
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IκB kinases (IKK), which stimulate the phosphorylation and ubiquitination-induced
degradation of IκB, as such releasing an active form of NF-κB.
IκB kinase (IKK) is a multi-subunit protein kinase consisting of two highly homologous
catalytic subunits, IKKα and IKKβ, which phosphorylate IκB and a non-enzymatic
regulatory subunit, IKKγ (also called NEMO, NF-κB essential modulator), which is
required for the activation of IKKα/IKKβ heterodimers in response to pro-inflammatory
cytokines, such as TNF-α and IL-1 [144-146]. Phosphorylation of IκB at two critical serine
residues (Ser32/Ser36 in IκBα and Ser19/Ser23 in IκBβ) in their N-terminal regulatory
domain by the IKK complex targets them for rapid polyubiquitination and subsequent
degradation by the 26S proteasome [147]. This IκB isoform phosphorylation is stimulus
specific, for example IκBβ is only phosphorylated by certain stimuli including LPS and
IL-1β, whereas most NF-κB activators trigger IκBα phosphorylation. This level of control
is also thought to impact on the cell type specificity and kinetics of the response, which in
turn can influence the duration of transcription.
In the classical pathway, it has been shown that IKK®, but not IKKα, is important in NF-
κB activation. Furthermore, it has been demonstrated that these two kinases have distinct
rather than overlapping functions [148-151]. The classical pathway includes signalling from
TLR/IL-1R family members, intracellular pattern recognition receptors including retinoic
acid inducible gene (RIG-I), melanoma differentiation associated factor-5 (MDA-5) and
protein kinase R (PKR), as well as signalling from the TNFR (reviewed by [152]).
Mediators such as lymphotoxin-β, CD40L and receptor activator of NF-κB ligand
(RANKL) activate the non-classical pathway [153, 154]. This pathway involves IKKα
phosphorylation, processing of the p52 precursor p100 and nuclear translocation of the
heterodimer p52/RelB and is believed to play a key role in adaptive immunity [155, 156].
The NF-κB pathway is further controlled by post-translation modifications, i.e.
phosphorylation and acetylation. These modulate the interaction of Rel proteins with other
components of the transcriptional machinery and alter their kinetics in and out of the
nucleus. The phosphorylation status of NF-κB can influence activation, e.g. phosphorylation
of RelA may enhance transcriptional activation. On the other hand phosphorylation of the
p50 precursor p105 can reduce its processing into p50 [157]. NF-κB can also associate with
other transcriptional proteins such as histone acetyltransferase and histone deacetylase
(reviewed by [158]). Acetylation of the Rel proteins can increase the time it is located in the
nucleus [159]. Furthermore recent data suggest that the phosphorylation and acetylation
steps occur stepwise, phosphorylation of RelA is required prior to and enhances acetylation
of Rel A in order to improve transcriptional activity of NF-κB [160].
As mentioned above, NF-κB targets different genes, encoding proteins that are associated
with mature DC, amongst these are cytokines (e.g. IL-6, IL-12, TNF-α), chemokines (e.g.
MIP-1α, MCP1), adhesion molecules (e.g. ICAM-1), inducible effector enzymes (e.g.
COX-2), as well as regulators of apoptosis (e.g. c-IAP, XIAP, Bcl-xL). Since, NF- κB
regulates so many different immune activation-related genes and hence controls the
properties of DC, tight regulation by negative feedback is required to avoid the generation of
chronic inflammatory milieu that can lead to autoimmunity. Several feedback molecules
have been described, including IκB, A20 (or TNF-α inducible protein 3, TNFAIP3),
tripartite-motif protein (TRIM) 30α and phosphatase PP2A, to name a few [161-166].
The remainder of this section will introduce A20, since A20 has been recently studied and
shown to be potentially interesting in view of enhancing tumour antigen-specific immune
responses. A20 was originally identified as a TNF-inducible gene in human umbilical vein
endothelial cells [167]. Subsequent research demonstrated that A20 is also induced in many
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other cell types, amongst which mouse and human DC [161, 168, 169]. A20 expression is
under the immediate control of NF-κB. Therefore, it is not surprising that A20 expression is
observed in response to various stimuli including TNF, IL-1 and TLR ligands [170-173].
Recently, it has been demonstrated that A20 is an ubiquitin-editing enzyme with de-
ubiquitinase activity in the N-terminal region and ubiquitinase activity in the zinc finger
domain of the C-terminal region. It is through this dual ubiquitin-editing function of A20,
that it can modulate down-regulation of NF-κB signalling, this through interaction with
several proteins of the TNF-, IL-1/TLR-signaling pathways, amongst which TRIF, RIP,
IRAK1, TRAF6, NEMO/IKKγ and IκB-kinases [169, 170, 172, 174-177]. Similar to NF-
κB, A20 can be further regulated by post-translational modification. An IKK-dependent
phosphorylation of A20 at Ser381 has been shown to increase the ability of A20 to inhibit
NF-κB activation. The mechanism, however, has yet to be elucidated [178]. The role of A20
in DC will be discussed in the section ‘down-regulation of feedback mechanisms’.
MODIFICATION OF DC IN ORDER TO MIMIC PERSISTENT TLR SIGNALLING
DC are considered to be the most potent antigen-presenting cells of the immune system, one
of the most well-studied vaccination approaches is the use of DC loaded ex vivo or in vivo
with TAA in one form or another to boost/induce anti-tumour immune responses in cancer
patients. Several approaches have been studied for loading DC with antigen, the description
of which is outside the scope of this review. Of these the most promising strategies
introduce the genetic information of the entire tumour antigen fused to MHC class II
targeting signals, hence obtaining antigen-presentation to both CD8+ and CD4+ T cells,
respectively [179, 180]. Broadly speaking, these genetic modification methods can be
divided in viral and non-viral methods, which have been reviewed in [14, 181-184]. In
recent years, these strategies have been employed to not only deliver TAA, but
simultaneously deliver signals that result in functional modification of DC, be it the
introduction of activation-inducing molecules for anti-tumour therapy or the introduction of
activation inhibitors, with the purpose of inducing antigen-specific tolerance.
CO-DELIVERY OF TUMOUR ANTIGEN AND CONSTITUTIVE ACTIVE TLR4
TO DC
Both mouse and human DC express TLR4, which binds LPS (aided by CD14 and MD-2),
resulting in DC maturation [185]. This is mediated by both NF-κB and MAPK [82, 117].
LPS-mediated activation has been shown to remarkably enhance the ability of DC to
stimulate antigen-specific immune responses in vitro. Moreover, it was reported that LPS-
activated DC could overcome suppression by Treg, a critical factor in anti-tumour
immunology [186]. However, the clinical use of LPS for immunotherapy is prohibited due
to cytotoxicity concerns as well as batch-to-batch variability. Therefore, several groups have
focused on the generation and evaluation of a constitutive active TLR4 (caTLR4) for DC
maturation [187-190]. Therefore, the TLR was truncated between positions M620 - P621
and linked to the nerve growth factor leader sequence [187, 189] or the leader sequence of
LAMP1 [188]. Alternatively the cytoplasmic domain of TLR4 was linked to the
extracellular single-chain immunoglobulin anti-erbB2 [190]. These caTLR4 molecules were
subsequently delivered to DC under the form of mRNA, either by transfection [187, 189] or
electroporation [188] or through retroviral transduction [190]. Evidence for NF-κB
activation upon introduction of caTLR4 was delivered and it was shown that DC modified
with this caTLR4, either [188] or not [187, 189] in combination with CD40L, become
mature. Moreover, these DC were able to stimulate CTL, specific for both the strong
immunogen MelanA and the weak immunogen Trp2 [187-189].
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Co-delivery of Tumour Antigen and Activation Signals to DC
With regard to activation of DC via TLR4, Hamdy et al. have shown that vaccination of B16
tumour bearing mice with PLGA nanoparticles co-encapsulating the poorly immunogenic
melanoma antigen, TRP2, along with the TLR4 ligand, 7-acyl lipid A, has therapeutic
effects [191]. With regard to co-delivery of TAA and TLR ligands in a one step
modification, we have demonstrated that electroporation can be applied for the simultaneous
delivery of TAA encoding mRNA and dsRNA, in particular Ampligen or poly(I:C12U),
which is a GMP-grade synthetic analogue of the TLR3 ligand, poly(I:C) and therefore
suitable for human and more importantly clinical use [26, 161]. This strategy resulted in up-
regulation of A20, thus suggesting activation of NF-κB [161]. Moreover, small amounts of
Ampligen were sufficient to induce fully mature DC, capable of efficiently stimulating
MelanA-specific immune responses [26].
Besides the delivery of these activation stimuli using non-viral strategies, it has been
repeatedly shown that many of the viral vector preparations used for delivery of antigens are
inherently activating DC [192-197]. It has been demonstrated that different virus types,
amongst which adenovirus, lentivirus (human immunodeficiency virus and equine anaemia
virus), as well as Moloney murine leukaemia virus, up-regulate co-stimulatory and antigen-
presenting molecules on DC. In case of adenoviral and lentiviral vectors, it has been further
shown that these induce production of Th 1 and pro-inflammatory cytokines, resulting in DC
with strong T cell stimulatory capacity. This can be explained by the triggering of
intracellular signalling pathways, such as those initiated by 2′,5′-oligoadenylate synthetases
(2′,5′-OAS) and PKR. Furthermore, it has been demonstrated in a 293T reporter assay that
lentiviruses can activate several TLR [192, 193]. Additionally, it has been shown that direct
administration of lentiviral vectors results in transduction of cells at the periphery, that these
cells migrate to lymphoid organs [198] and are able to stimulate antigen-specific immune
responses [199-204]. The latter two observations further deliver circumstantial evidence for
the capacity of lentiviral vectors to activate DC.
Delivery of Signal Adaptor Molecules to DC (Fig. 3)
DC function can effectively be modulated using gene therapy techniques by the introduction
of genes that control DC differentiation and maturation. NF-κB has been one of the first
pathways to be targeted in DC as an adjuvant strategy. In this case, NF-κB inducing kinase
(NIK) was over-expressed using adenovirus vectors. NIK over-expression increased DC
maturation as assessed by up-regulation of co-stimulatory molecules, MHC molecules and
secretion of pro-inflammatory cytokines [205]. In this context, co-expression of NIK with
GFP significantly increased Th1 GFP-specific immune responses, although the relevance of
this strategy in anti-viral or anti-tumour immunity was not assessed [205]. Another strategy
has been the introduction of MyD88, TRIF or IRAK-1, all major TLR adaptor molecules,
which when over-expressed were shown to transduce downstream signals without TLR
stimuli. Akazawa et al. [206] successfully introduced MyD88 and TRIF in mouse DC using
lentiviral vectors, resulting in DC with different properties. MyD88-modified DC produced
IL-6 and IL-12p40, but showed no up-regulation of phenotypic markers, whereas TICAM-1
introduction stimulated interferon IFN-α production and had enhanced levels of CD86. Both
MyD88 and TRIF augmented the allo-stimulatory capacity of the DC. Moreover, antigen-
specific responses could be efficiently induced and tumour outgrowth was delayed by
immunization with these MyD88- and TRIF-modified DC [207]. Xu et al. generated
retroviral vectors encoding the chimeric proteins consisting of the extracellular single-chain
immunoglobulin anti-erbB2 linked to an intracellular TLR-signalling component composed
of either MyD88 or IRAK-1. Their experiments were performed in the DC line, JAWS II, in
which only the IRAK-1 chimera was able to mediate IL-12 and TNF-α secretion. The latter
was subsequently, evaluated for its capacity to enhance the T cell stimulatory capacity of
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DC, demonstrating enhanced ovalbumin-specific OT-II CD4+ T cell responses [190]. A
fourth study targeted NF-κB activation in DC using lentiviral vectors, by expressing
Kaposi’s sarcoma associated human herpes virus (KSHV) vFLIP [208]. In this case, DC
maturation was enhanced by up-regulation of MHC I and II, co-stimulatory molecules
CD80, CD86, CD40 and ICAM-I. In addition, increased antigen-specific CD8+ T cell
responses and expression of TNF-α and IL-12 was achieved and an enhanced anti-tumour
and anti-parasite immunity were demonstrated [208, 209].
As already discussed, another group of signalling pathways with a critical role in DC
function is the MAPK family. MAPK pathways regulate DC maturation and modulate the
type of immune response in concert with NF-κB and other pathways. Therefore, the specific
delivery of antigen with modulators of MAPK pathways to DC could enhance antigen-
specific immune responses or induce antigen-specific immune suppression. Additionally,
activation of individual MAPK pathways in the absence of TLR stimulation could dissect
the specific role of each individual pathway in DC function. This could potentially lead to a
fine-tuning of DC-dependent immune responses. MAPK have been recently targeted in DC
using LV, by expression of selected constitutive activated mutants of the three main MAPK
pathways [100].
MAPK ERK and p38 were activated by expressing MEK1 and MKK6 mutants containing
glutamate and aspartate residues in their activation loop, mimicking activating
phosphorylated serine or threonine residues [210]. A fusion protein between MKK7 and
JNK1 was expressed to achieve constitutive JNK1 phosphorylation [211]. In addition,
expression of constitutive activators prevents inactivation by negative feedback mechanisms
such as MAPK phosphatase activities, which may be important to counteract tolerogenic
mechanisms in anti-tumour immunity. In the absence of TLR stimulation, p38 activation
resulted in a DC maturation phenotype different from full maturation as achieved by LPS
treatment [100]. No specific effects on MHC levels or CD86 were observed. On the other
hand, there was specific up-regulation of CD80, CD40 and ICAM-I. Additionally, no
significant secretion of pro-inflammatory cytokines IL-12, TNF-α, IL-1β or IL-23 was
detected [100], in contrast to studies using p38 inhibitors in the context of TLR stimulation
[117-119].
Therefore, p38 activation would not be directly involved in transcriptional up-regulation of
cytokine genes, as suggested by other studies [121]. Interestingly, co-expression of OVA
with the p38 activator in DC significantly increased antigen-specific CD4+ and CD8+ T cell
responses leading to increased anti-tumour immunity [100, 209]. MAPK p38 constitutive
activation also increased CD8+ T cell responses to human tumour antigens NY-ESO in an
HLA-A2 humanised transgenic mouse model, and MelanA/MART-1 in a human DC-T cell
culture [100].
Specific activation of JNK1 in DC showed only a moderate up-regulation of CD80 and
ICAM-I and no significant secretion of pro-inflammatory cytokines. These results confirmed
previous studies with inhibitors showing that in comparison with p38, JNK marginally
control DC maturation [100, 128]. Nevertheless, increased antigen-specific CD8+ T cell
responses were detected after subcutaneous vaccination with LV expressing MKK7-JNK1,
suggesting that JNK1 may play a subtle but still important role in DC in vivo [100].
In the absence of TLR stimulation, constitutive ERK activation in DC resulted in an
immature phenotype with down-regulated CD40 and increased TGF-β expression [100].
Curiously, in contrast to abundant published literature on the subject, ERK constitutive
activation did not induce IL-10 secretion [76, 77, 99-105]. This situation may be analogous
to that of p38 and IL-12 secretion. ERK activation may be important but not sufficient for
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high-level secretion of IL-10. Interestingly, co-expression of the ERK activator with an
OVA transgene in DC led to impaired OVA-specific CD4+ and CD8+ T cell responses and
systemic increase in Foxp3 Treg [100]. Therefore, constitutive activation of ERK in the
absence of TLR stimulation can effectively suppress antigen-specific immune responses.
DOWN-REGULATION OF FEEDBACK MECHANISMS
As mentioned above, A20 is one of the feedback regulators of NF-κB. A20 shares some
similarities with IκBα, another feedback regulator. For one, the expression of both is
controlled by NF-κB and shows similar temporal profiles [212]. However, IκBα directly
inhibits NF-κB, while A20 functions upstream to deactivate several adaptor molecules of
the TNFR, IL-1/TLR signalling through its ubiquitinating/de-ubiquitinating properties. In
this way, A20 controls IKK and thus the degradation of IκBα. Recent studies demonstrate
that A20 is expressed in mouse DC activated with LPS (TLR4) [168], as well as in human
DC activated with poly(I:C) or through electroporation with its clinically acceptable
analogue, Ampligen [161]. This led to the hypothesis that down-regulation of A20 would
result in prolonged NF-κB activation, hence mimicking persistent TLR ligation and as such
resulting in DC with enhanced stimulatory capacity. RNA interference through introduction
of a lentivirally delivered shRNA or through introduction of siRNA, respectively, was
applied to down-regulate A20 [161, 168]. Both Song et al. and we demonstrated that A20
plays a crucial part in controlling the maturation, cytokine production and
immunostimulatory potency of the DC [168]. While, we focused on the expression pattern
of NF-κB, the secretion of cytokines, in particular IL-10 and IL-12 and their role in
stimulation of MelanA-specific T cells, Song et al. focused on the ability of the DC to
stimulate antigen-specific CTL and the effect of Treg on both DC and effector T cells.
In summary, human DC with down-regulated A20 expression have higher levels of NF-κB
and show enhanced and sustained secretion of both IL-10 and IL-12. IL-10 was shown to
negatively influence T cell proliferation, whereas IL-12 had an impact on Th 1 cell
induction. In general these DC were more potent in the stimulation of MelanA-specific
CD8+ T cells [161]. Mouse DC with down-regulated A20 expression showed spontaneous
and enhanced expression of co-stimulatory molecules and pro-inflammatory cytokines,
where refractory to Treg inhibition and activated tumour-infiltrating CTL and Th cells that
in turn were unresponsive to Treg mediated suppression [168]. These studies identify A20 as
an antigen-presentation attenuator and an ideal target in view of anti-tumour
immunotherapy, since it not only enables the DC to induce strong effector T cell responses
and it suppresses the suppressors, the Treg.
FUTURE PERSPECTIVES
DC play a crucial role in regulating both innate and adaptive immunity. Accordingly, DC
present many pathogen recognition receptors such as TLR that enable them to detect
potential threats such as viruses and bacteria. TLR engagement leads to the activation of NF-
κB and MAPK through MyD88 and TRIF-dependent pathways in a series of down-stream
kinase cascades. The implication of each MAPK pathway in DC function and immunity has
been extensively characterised by the use of specific MAPK inhibitors and by single
activation of MAPK pathways. In this way, MAPK p38 plays a major role in regulating
inflammatory immune responses, leading to increased immunisation, while JNK pathways
play a secondary role (although probably important in vivo). ERK activity is linked to
secretion of suppressive cytokines IL-10 and TGF-β and its activity is clearly linked to
immune suppression and tolerance. On the other hand NF-κB, a transcription factor that can
be induced upon stimulation with a variety of different stimuli, has always been associated
with maturation of DC and their capacity to stimulate potent T cell responses, as well as to
Breckpot and Escors Page 13
Endocr Metab Immune Disord Drug Targets. Author manuscript; available in PMC 2009 December 22.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
overcome Treg, hence with immune activation. Finally, NF-κB and MAPK pathways can be
modulated in DC by gene therapy techniques, leading to either immune activation and
increased immunity, or immune suppression and tolerance.
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Fig. (1).
Anti-tumour immunity and tumour-induced suppression. In this figure, the four main
mechanisms involving DC-T cell interaction in the regulation of tumour immunity are
shown. (A) In an effective anti-tumour immunotherapy, mature DC (mDC) present TAA on
their surface, represented as circled As. These antigens are recognised by specific CD4 and
CD8 T cells in a pro-inflammatory setting (in the presence of the depicted cytokines),
leading to differentiation of Th cells and CTL (T effector cells, Tef) from CD4 and CD8 T
cells, respectively. (B) Antigen presentation also takes place in the tumour environment. In
this setting, antigen-presenting cells such as DCreg induce antigen-specific and polyclonal
tolerance leading to tumour-induced immune suppression. In the figure, a tumour-associated
DCreg secretes tolerogenic cytokines IL-10 and TGF-β and converts other non-commited
DC into tolerogenic DC. In an analogous manner as in A, antigens are presented to CD4 and
CD8 T cells, which do not further differentiate into effector T cells. (C) Most TAA are
either auto-antigens or mutated auto-antigens (quasi-auto-antigens). Therefore, natural T
regulatory cells (nTreg) recognise these TAA both in the context of mature DC and
immature DC (iDC) by high-affinity binding of their TCR (depicted in the picture as parallel
bars between DC and nTreg). These natural Treg actively suppress DC and T effector cells
by several mechanisms not yet well characterised. (D) Tumour-associated DCreg present
TAA to naive and memory CD4 T cells in the context of a suppressive environment, in the
presence of cytokines such as IL-10 and TGF-β, as in (B). In this situation, CD4 T cells
differentiate into induced Treg (iTreg). There is increasing evidence that induced Treg can
suppress immune responses in similar ways to natural Treg, as in (C).
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Fig. (2).
Schematic representation of the MAPK and NF-κB pathway that are reported to enhance
DC maturation. The MAPK pathway is activated upon TLR stimulation, whereas activation
of the transcription factor NF-κB can be initiated by a variety of stimuli, resulting in the so-
called canonical or classical pathway, initiated upon ligation of TLR, RNA helicase and
PKR versus the non-classical pathway, initiated by stimuli, such as CD40L, lymphotoxin-β
or RANKL. The MAPK p38 aids the binding of NF-κB to its consensus sequence by
altering the chromatin structure of the DNA. Both the MAPK JNK and NF-κB pathway are
important in DC maturation. They drive the expression of co-stimulatory, adhesion and
antigen-presenting molecules, as well as pro-inflammatory cytokines. Moreover, NF-κB
drives the expression of several feedback proteins that attenuate activation, hence avoiding
chronic inflammation. One of these, the zinc finger protein A20, which has ubiquitinating
and de-ubiquitinating enzymatic activity, interacts with several adaptor proteins and has
been studied as a mode to mimic persistent DC activation, as such enhancing the DC’s
potency to stimulate tumour antigen-specific T cells.
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Fig. (3).
Targeting intracellular signalling pathways by genetic modification of DC. Gene therapy
techniques allow the modification of DC function by introducing specific genes that modify
intracellular signalling pathways. These signalling pathways will ultimately modify DC
function by either increasing or suppressing their immunogenicity. In the figure, a viral
vector carrying the therapeutic genes binds to the cell membrane (receptor recognition) and
it fuses directly to the cell membrane leading to the core release. As it is the case of other
vectors either based on retroviruses or not, virus-like particles can also be internalised by
endocytosis. In the case of lentivectors (and other retrovirus-based vectors), through a
process of reverse transcription, the therapeutic genetic information encoded as RNA is
copied into a DNA version that is transported to the cell nucleus. Then, the therapeutic DNA
genes are incorporated into the host genome, and they will lead to transcription and
translation of both TAA and modulators of DC signalling (DC modulators). In this case,
activation of ERK, JNK, p38 and NF-κB is depicted. Activation of these pathways will
regulate DC maturation phenotype and cytokine secretion, and ultimately will enhance
presentation of TAA to specific CD4 and CD8 T cells as shown in Fig. (1).
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